Reuters-July 7, 2015
Analyst stated this morning that the 18 month target for Cosentyx, a Novartis Blockbuster in Immunology, is just over 53% of the PsO market or $3.5b in domestic sales alone. An additional $6.2b in sales is forecasted in the U.S. over the next 20 months from the anticipated fast track indications that include PsA, RA and CD. IL17 has longed been believed to be a key cellular player in the inflammation and pain cascade and provides patients with a new modality for treatment. Previous gold standards, Amgen's Enbrel and JnJ's Remicadeare believed to already be in rapid decline due the anticipation of Cosentyx to the market. Johnson and Johnson unveiled several new products and disease states in the last 24 months to head off the financial impact but both faced lack luster sales. Novartis ended trading up 17.8% for the year.
Bad news for the drug sector at Janssen.
Analyst stated this morning that the 18 month target for Cosentyx, a Novartis Blockbuster in Immunology, is just over 53% of the PsO market or $3.5b in domestic sales alone. An additional $6.2b in sales is forecasted in the U.S. over the next 20 months from the anticipated fast track indications that include PsA, RA and CD. IL17 has longed been believed to be a key cellular player in the inflammation and pain cascade and provides patients with a new modality for treatment. Previous gold standards, Amgen's Enbrel and JnJ's Remicadeare believed to already be in rapid decline due the anticipation of Cosentyx to the market. Johnson and Johnson unveiled several new products and disease states in the last 24 months to head off the financial impact but both faced lack luster sales. Novartis ended trading up 17.8% for the year.
Bad news for the drug sector at Janssen.
How immunology died
Aucun commentaire:
Enregistrer un commentaire